Anne B.S. Giersch

Dr. Anne B.S. Giersch


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2025 in Clinical Chemistry
Verified
Journal Article
Closed access
PDF file
AGAnne B.S. Giersch
Anne B.S. Giersch
CMCynthia C Morton
Cynthia C Morton
Background: Newborn hearing screening is a physiologic screen to identify infants who may be deaf or hard of hearing (DHH) and would benefit from early intervention. Typically, an infant who does not pass the newborn hearing screen is referred for clinical audiology testing, which may be followed by genetic testing to identify the etiology of an infant’s DHH. Content: The current newborn hearing screening paradigm can miss mild cases of DHH or later-onset DHH, leaving a child at risk for unrecognized DHH, which could impact long-term language, communication, and social development. Genomic technologies are improving the diagnosis of DHH in newborns who fail their newborn hearing screen, and a case is being made for genomic screening for DHH in all newborns. Summary: The genomic era brings a wealth of opportunities to screen newborns for genetic causes of hearing loss on a population wide basis, some of which are already being implemented in a clinical setting.

Verified
Journal Article
Open access
PDF file
CMCalli O. Mitchell
Calli O. Mitchell
GRGreysha Rivera-Cruz
Greysha Rivera-Cruz
MCMatthew Hoi Kin Chau
Matthew Hoi Kin Chau
ZDZirui Dong
Zirui Dong
KCKwong Wai Choy
Kwong Wai Choy
CMCynthia C. Morton
Cynthia C. Morton
Recent advances in genomic sequencing technologies have expanded practitioners’ utilization of genetic information in a timely and efficient manner for an accurate diagnosis. With an ever-increasing resource of genomic data from progress in the interpretation of genome sequences, clinicians face decisions about how and when genomic information should be presented to families, and at what potential expense. Presently, there is limited knowledge or experience in establishing the value of implementing genome sequencing into newborn screening. Herein we provide insight into the complexities and the burden and benefits of knowledge resulting from genome sequencing of newborns.

7 May 2026 in Histopathology
Verified
Journal Article
Closed access
PDF file
CWCharlotte I Wang
Charlotte I Wang
SJSoma Jobbagy
Soma Jobbagy
AGAnne B.S. Giersch
Anne B.S. Giersch
JGJonathan B Greer
Jonathan B Greer
Kevin X. LiuKevin X. Liu
Kevin X. Liu
ICIvan Chebib
Ivan Chebib

9 April 2021 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
AGAnne B.S. Giersch
Anne B.S. Giersch
JSJun Shen
Jun Shen
KBKevin TA Booth
Kevin TA Booth
YCYvonne Chekaluk
Yvonne Chekaluk
MCMichael Cohen
Michael Cohen
CMCynthia C. Morton
Cynthia C. Morton

1 April 2021 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
LSLaura Sack
Laura Sack
LMLauren Mertens
Lauren Mertens
EMElissa Murphy
Elissa Murphy
AGAnne B.S. Giersch
Anne B.S. Giersch
HMHeather Mason-Suares
Heather Mason-Suares

3 October 2024 in Clinical Chemistry
Verified
Journal Article
Open access
PDF file
AGAnne B.S. Giersch
Anne B.S. Giersch
Mosaic copy number variants (CNV) occur postfertilization and, depending on how early in embryonic/fetal development it occurs, the variant may be present in only a fraction of cells. Additionally, the variant may not be in all tissue types or in the same proportion of cells in different organs. These factors complicate the detection of mosaic CNVs, particularly if standard sequence analysis algorithms are used.